Drug Companies Update Sept 2007
Mergers, acquisitions & Joint Ventures
- Alteon has changed its name to Synvista Therapeutics.
- Merck & Co have acquired NovaCardia, a clinical-stage pharmaceutical company focused on cardiovascular disease.
- Australian biotech company Peptech has acquired Evogenix.
New Companies
- Norwegian company, Bio-Medisinsk Innovasjon develops drugs based on compounds that interfere with serotonin.
- DiaMedica is developing treatments for all stages of Type II diabetes, by repostioning existing drugs and developing NCEs.
- Diasome Pharmaceuticals uses its nanotechnology cell receptor targeted delivery system to deliver insulin to hepatocytes.
- HUYA Bioscience International identifies and licenses Chinese pharmaceuticals for commercialization in the Western markets.
- Laboratorios Leti is a private biopharmaceutical healthcare company focused on allergy, diagnostics, vaccines, dermatolgy and personal care.
- Privately-owned company Particle Therapeutics is focused on the development of powder injections for unmet medical needs.
- Privately-owned company Theracos develops novel therapeutic agents for diseases with significant unmet medical needs.
-
Biotechnology company TheraVitae develops adult stem cell therapeutics.
- Tikvah Therapeutics is focusing on the development of compounds for the treatment of neurological and psychiatric disorders.
- TMRC focuses on the research and development of anticancers, which it outlicences to other companies.
- Validus Pharmaceuticals is engaged in acquiring, reformulating and marketing prescription products relevant to the psychiatric and neurology markets.
